title: Midkine as a novel target for antibody therapy in osteosarcoma.
abstract: Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P<0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas.
authors.affiliation: Department of Orthopedics, University of the Ryukyus Faculty of Medicine, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Maehara
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kaname
authors.forename: Kumiko
authors.initials: K
authors.lastname: Yanagi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hanzawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Owan
authors.forename: Takao
authors.initials: T
authors.lastname: Kinjou
authors.forename: Kenji
authors.initials: K
authors.lastname: Kadomatsu
authors.forename: Shinya
authors.initials: S
authors.lastname: Ikematsu
authors.forename: Teruo
authors.initials: T
authors.lastname: Iwamasa
authors.forename: Fuminori
authors.initials: F
authors.lastname: Kanaya
authors.forename: Kenji
authors.initials: K
authors.lastname: Naritomi
mesh_terms: D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000737:chemistry*; D001859:Bone Neoplasms / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002648:Child; D016207:Cytokines / Q000737:chemistry* / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods*; D000078792:Midkine; D012516:Osteosarcoma / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D000906:Antibodies; D016207:Cytokines; D000078792:Midkine